| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 57 | 2022 | 369 | 6.890 |
Why?
|
| Receptor, ErbB-2 | 15 | 2022 | 41 | 2.630 |
Why?
|
| Antineoplastic Agents | 16 | 2019 | 169 | 1.550 |
Why?
|
| Trastuzumab | 13 | 2021 | 21 | 1.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2022 | 222 | 1.350 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 184 | 1.130 |
Why?
|
| Neoplasm Metastasis | 17 | 2019 | 91 | 0.940 |
Why?
|
| Antibodies, Monoclonal | 12 | 2011 | 185 | 0.920 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2021 | 12 | 0.850 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 30 | 0.790 |
Why?
|
| Female | 61 | 2022 | 14273 | 0.730 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 10 | 0.670 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 4 | 0.660 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 45 | 0.660 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 31 | 0.650 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 7 | 0.630 |
Why?
|
| Middle Aged | 41 | 2021 | 8403 | 0.620 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 57 | 0.620 |
Why?
|
| Aromatase Inhibitors | 4 | 2012 | 8 | 0.570 |
Why?
|
| Humans | 67 | 2022 | 25692 | 0.550 |
Why?
|
| Tamoxifen | 6 | 2012 | 26 | 0.550 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2012 | 18 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 14 | 2014 | 84 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 33 | 0.450 |
Why?
|
| Adult | 34 | 2020 | 7336 | 0.440 |
Why?
|
| Estrogen Replacement Therapy | 3 | 1999 | 20 | 0.430 |
Why?
|
| Enzyme Inhibitors | 4 | 2006 | 118 | 0.410 |
Why?
|
| Aged | 30 | 2020 | 8501 | 0.390 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2014 | 13 | 0.360 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 21 | 0.350 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 4459 | 0.350 |
Why?
|
| Menopause | 2 | 2000 | 92 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 39 | 0.300 |
Why?
|
| Treatment Outcome | 13 | 2021 | 3231 | 0.290 |
Why?
|
| Prospective Studies | 4 | 2021 | 1633 | 0.290 |
Why?
|
| ErbB Receptors | 2 | 2008 | 52 | 0.280 |
Why?
|
| Neoplasm Staging | 10 | 2019 | 315 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2019 | 198 | 0.260 |
Why?
|
| Prognosis | 5 | 2018 | 739 | 0.250 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 62 | 0.240 |
Why?
|
| Registries | 3 | 2021 | 170 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2016 | 69 | 0.240 |
Why?
|
| Survival Analysis | 7 | 2018 | 246 | 0.230 |
Why?
|
| Receptors, Estrogen | 7 | 2013 | 56 | 0.230 |
Why?
|
| Survival Rate | 5 | 2019 | 308 | 0.230 |
Why?
|
| Young Adult | 2 | 2019 | 1855 | 0.210 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 152 | 0.210 |
Why?
|
| Quinazolines | 2 | 2016 | 14 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2022 | 9 | 0.210 |
Why?
|
| Quality of Life | 9 | 2007 | 600 | 0.200 |
Why?
|
| Combined Modality Therapy | 5 | 2018 | 281 | 0.190 |
Why?
|
| Bevacizumab | 7 | 2014 | 19 | 0.190 |
Why?
|
| Cell Proliferation | 2 | 2019 | 167 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1987 | 154 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 3 | 1987 | 146 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 1689 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 68 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 15 | 0.180 |
Why?
|
| Stroke Volume | 2 | 2019 | 49 | 0.170 |
Why?
|
| Isoflavones | 1 | 2000 | 2 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2019 | 1781 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 15 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 14 | 0.170 |
Why?
|
| Gene Targeting | 1 | 2019 | 8 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 6 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 14 | 0.160 |
Why?
|
| S Phase | 1 | 1999 | 10 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 35 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2018 | 244 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 51 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 75 | 0.150 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 221 | 0.150 |
Why?
|
| Chimerism | 1 | 2018 | 3 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 4 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 4 | 0.150 |
Why?
|
| Disease Management | 1 | 2018 | 97 | 0.150 |
Why?
|
| Mammography | 3 | 2022 | 41 | 0.150 |
Why?
|
| Fenretinide | 2 | 1994 | 3 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 410 | 0.140 |
Why?
|
| Paclitaxel | 4 | 2013 | 41 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 584 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 284 | 0.130 |
Why?
|
| Survivors | 4 | 2004 | 67 | 0.130 |
Why?
|
| Postmenopause | 4 | 2009 | 53 | 0.130 |
Why?
|
| Cytostatic Agents | 1 | 2016 | 2 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 41 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2016 | 311 | 0.130 |
Why?
|
| Aspirin | 1 | 2016 | 74 | 0.120 |
Why?
|
| Male | 7 | 2021 | 13917 | 0.120 |
Why?
|
| Hypertension | 2 | 2014 | 201 | 0.120 |
Why?
|
| Gene Amplification | 2 | 2013 | 18 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 450 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 66 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1994 | 1 | 0.110 |
Why?
|
| Genes, erbB-2 | 2 | 2005 | 7 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2005 | 66 | 0.110 |
Why?
|
| Animals | 2 | 2019 | 3510 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 140 | 0.110 |
Why?
|
| Genes, BRCA2 | 2 | 2020 | 7 | 0.110 |
Why?
|
| Estrogens | 3 | 2000 | 25 | 0.110 |
Why?
|
| Genes, BRCA1 | 2 | 2020 | 9 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 3 | 2000 | 37 | 0.110 |
Why?
|
| Deoxycytidine | 3 | 2011 | 23 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 25 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 2005 | 209 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 259 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 1993 | 132 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2012 | 72 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3220 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2005 | 81 | 0.090 |
Why?
|
| Disease Progression | 5 | 2008 | 664 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2005 | 341 | 0.080 |
Why?
|
| Diet | 2 | 2002 | 207 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2000 | 2 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2000 | 6 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2008 | 152 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 8 | 0.080 |
Why?
|
| Mastectomy | 1 | 2009 | 35 | 0.080 |
Why?
|
| Safety | 4 | 2002 | 40 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2005 | 15 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2004 | 47 | 0.080 |
Why?
|
| Mutation | 3 | 2018 | 325 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 913 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 16 | 0.080 |
Why?
|
| Pyrroles | 1 | 2008 | 19 | 0.070 |
Why?
|
| Indoles | 1 | 2008 | 35 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 9 | 0.070 |
Why?
|
| Contraindications | 3 | 1998 | 26 | 0.070 |
Why?
|
| Carcinoma | 1 | 2008 | 63 | 0.070 |
Why?
|
| Longevity | 2 | 2000 | 27 | 0.070 |
Why?
|
| Etoposide | 1 | 1987 | 25 | 0.070 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2004 | 7 | 0.070 |
Why?
|
| Breast Self-Examination | 1 | 2007 | 3 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2003 | 17 | 0.070 |
Why?
|
| Drug Interactions | 2 | 1998 | 36 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 332 | 0.070 |
Why?
|
| Family | 1 | 2007 | 94 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2004 | 299 | 0.060 |
Why?
|
| Logistic Models | 3 | 2005 | 366 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 123 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 140 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2005 | 56 | 0.060 |
Why?
|
| Mass Screening | 2 | 2022 | 168 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 128 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2000 | 340 | 0.060 |
Why?
|
| Gene Expression | 1 | 2005 | 182 | 0.060 |
Why?
|
| Recurrence | 1 | 2005 | 275 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2005 | 284 | 0.060 |
Why?
|
| Capecitabine | 3 | 2011 | 3 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2004 | 6 | 0.060 |
Why?
|
| Fluorouracil | 3 | 2011 | 41 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1995 | 95 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 4 | 0.050 |
Why?
|
| Drug Evaluation | 6 | 1989 | 19 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 392 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2002 | 3 | 0.050 |
Why?
|
| Nitriles | 1 | 2002 | 13 | 0.050 |
Why?
|
| Triazoles | 1 | 2002 | 28 | 0.050 |
Why?
|
| Quinolines | 1 | 2022 | 7 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 554 | 0.050 |
Why?
|
| Heart Diseases | 2 | 2001 | 60 | 0.050 |
Why?
|
| Hospitalization | 1 | 2004 | 292 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2003 | 138 | 0.050 |
Why?
|
| Risk Factors | 4 | 2005 | 2224 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 90 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2002 | 87 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 351 | 0.050 |
Why?
|
| Genotype | 2 | 2014 | 326 | 0.050 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Health Behavior | 1 | 2002 | 136 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2020 | 16 | 0.040 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2000 | 1 | 0.040 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 2000 | 1 | 0.040 |
Why?
|
| Phytoestrogens | 1 | 2000 | 4 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2000 | 4 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 7 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2000 | 10 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2000 | 4 | 0.040 |
Why?
|
| Menopause, Premature | 1 | 2000 | 5 | 0.040 |
Why?
|
| Plant Preparations | 1 | 2000 | 7 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 32 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2000 | 33 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 36 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1999 | 85 | 0.040 |
Why?
|
| Weight Gain | 1 | 2000 | 62 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Time Factors | 2 | 2002 | 1336 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 27 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2000 | 396 | 0.040 |
Why?
|
| Anthracyclines | 2 | 2008 | 15 | 0.040 |
Why?
|
| Taxoids | 2 | 2008 | 10 | 0.040 |
Why?
|
| Flushing | 1 | 1998 | 3 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 3 | 0.040 |
Why?
|
| Dyspareunia | 1 | 1998 | 5 | 0.040 |
Why?
|
| Vaginitis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 1998 | 7 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 1998 | 12 | 0.040 |
Why?
|
| Mood Disorders | 1 | 1998 | 27 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 1084 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 1989 | 509 | 0.040 |
Why?
|
| Obesity | 1 | 2000 | 290 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2011 | 11 | 0.030 |
Why?
|
| Osteoporosis | 1 | 1998 | 68 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 7 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 15 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 1998 | 111 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 10 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 9 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 13 | 0.030 |
Why?
|
| Echocardiography | 1 | 2016 | 88 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 20 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 134 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 2076 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 22 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1994 | 8 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 110 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 264 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2014 | 185 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2011 | 1 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neoplasms | 1 | 1994 | 224 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 43 | 0.020 |
Why?
|
| Vidarabine Phosphate | 1 | 1989 | 1 | 0.020 |
Why?
|
| Arabinonucleotides | 1 | 1989 | 1 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 1989 | 1 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1989 | 18 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1989 | 16 | 0.020 |
Why?
|
| Premenopause | 1 | 2009 | 9 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 11 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1989 | 43 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 110 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 45 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1989 | 70 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 119 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 11 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2008 | 1 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 66 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 9 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2000 | 1962 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 30 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 103 | 0.020 |
Why?
|
| Fatigue | 1 | 2008 | 55 | 0.020 |
Why?
|
| Culture Media | 1 | 1987 | 29 | 0.020 |
Why?
|
| Cell Division | 1 | 1987 | 79 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1987 | 55 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1987 | 110 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1987 | 127 | 0.020 |
Why?
|
| Cell Line | 1 | 1987 | 268 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 228 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 20 | 0.020 |
Why?
|
| Thiadiazoles | 1 | 1986 | 1 | 0.020 |
Why?
|
| Illinois | 1 | 2007 | 223 | 0.020 |
Why?
|
| Poverty | 1 | 2007 | 92 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1987 | 495 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 71 | 0.020 |
Why?
|
| Women's Health | 1 | 2007 | 157 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 80 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2005 | 120 | 0.020 |
Why?
|
| Oncology Nursing | 1 | 2004 | 2 | 0.020 |
Why?
|
| Patient Selection | 1 | 2005 | 170 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1983 | 4 | 0.010 |
Why?
|
| Imidazoles | 1 | 2004 | 53 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 2 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2003 | 11 | 0.010 |
Why?
|
| Axilla | 1 | 2002 | 13 | 0.010 |
Why?
|
| Mesonephroma | 1 | 1982 | 1 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 13 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2002 | 11 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1982 | 10 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 43 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 170 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 443 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 48 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2001 | 36 | 0.010 |
Why?
|
| Fever | 1 | 2001 | 30 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 45 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 716 | 0.010 |
Why?
|
| Palliative Care | 1 | 2001 | 99 | 0.010 |
Why?
|
| United States | 1 | 2005 | 1943 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 847 | 0.010 |
Why?
|
| Pain | 1 | 2001 | 372 | 0.010 |
Why?
|
| Translations | 1 | 1997 | 11 | 0.010 |
Why?
|
| Self Concept | 1 | 1997 | 39 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2002 | 1077 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 472 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 646 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 75 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1994 | 12 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 28 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1994 | 48 | 0.010 |
Why?
|
| Cisplatin | 1 | 1994 | 49 | 0.010 |
Why?
|
| Anthracenes | 1 | 1983 | 5 | 0.000 |
Why?
|
| Tomography | 1 | 1982 | 13 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1982 | 25 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1982 | 163 | 0.000 |
Why?
|
| Mortality | 1 | 1982 | 80 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1982 | 235 | 0.000 |
Why?
|